CSL sales and marketing update

CSL's CSL Behring subsidiary launched the My Access cost share program, which covers up to $12,000 in annual out-of-pocket costs of a CSL Behring therapy for hemophilia A or von Willebrand disease (vWD) for patients in the U.S. who have private insurance. The company said the patient's private insurance must cover their CSL Behring therapy. My Access will be available through CSL Behring's My Source program, which offers information, financial support programs and community connections for the bleeding disorders community. ...